业务咨询
中国:
Email: marketing@medicilon.com.cn
业务咨询专线:400-780-8018
(仅限服务咨询,其他事宜请拨打川沙总部电话)
川沙总部电话: +86 (21) 5859-1500
海外:
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
Developing novel drugs that can abrogate the growth and metastasis of malignant tumors is a major challenge for cancer researchers. WYC-209, a synthetic retinoid, inhibits proliferation of malignant murine melanoma tumor-repopulating cells (TRCs). The enantiomers WYC-209A and WYC-209B exhibit similar TRC inhibition activities. The binding assay by surface plasmon resonance (SPR) analysis shows that WYC-209A and WYC-209B acid bind to RARs at nano-molar doses. SPR was carried out by Medicilon, using the Biacore 8K equipment.
Reference